Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Acta Orthop ; 89(2): 229-233, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29231771

RESUMEN

Background and purpose - A significant number of patients with spinal metastases are treated non-surgically, but may need surgical treatment at a later stage due to progression of symptoms. Therefore, we investigated the need for late surgical decompression in patients with spinal metastasis who were initially deemed as non-surgical candidates, as well as the outcome of late surgery. Patients and methods - 116 patients who were referred to the orthopedic oncology department between 2002 and 2011 due to spinal metastasis with neurologic symptoms were deemed to be non-surgical candidates. The primary reason was minor neurologic deficits in 40 patients (M) and short survival (S) in 76 patients. Results - 8 patients underwent a late operation due to progression of the neurologic symptoms, all of them belonged to group M. M-patients with a modified Bauer score of less than 2 had both an inferior survival as well as a higher risk for late surgery. Postoperative improvement in neurologic function was noted in 5/8 operated patients, whilst 2 patients had stationary symptoms and 1 deteriorated. Interpretation - The need for late surgery arises in a minority of patients with spinal metastasis primarily treated non-surgically, and only in patients with minor neurologic compromise rather than poor general condition. An established prognostic score (modified Bauer) can be used to guide decision-making. Late surgical decompression is effective in restoring the neurologic status.


Asunto(s)
Descompresión Quirúrgica , Vértebras Lumbares , Compresión de la Médula Espinal/cirugía , Neoplasias de la Columna Vertebral/secundario , Neoplasias de la Columna Vertebral/cirugía , Vértebras Torácicas , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Selección de Paciente , Estudios Retrospectivos , Compresión de la Médula Espinal/etiología , Neoplasias de la Columna Vertebral/mortalidad , Tasa de Supervivencia , Resultado del Tratamiento
2.
Acta Orthop ; 88(3): 341-347, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28266233

RESUMEN

Purpose - We wanted to examine the potential of the Scandinavian Sarcoma Group (SSG) Central Register, and evaluate referral and treatment practice for soft-tissue sarcomas in the extremities and trunk wall (STS) in the Nordic countries. Background - Based on incidence rates from the literature, 8,150 (7,000-9,300) cases of STS of the extremity and trunk wall should have been diagnosed in Norway, Finland, Iceland, and Sweden from 1987 through 2011. The SSG Register has 6,027 cases registered from this period, with 5,837 having complete registration of key variables. 10 centers have been reporting to the Register. The 5 centers that consistently report treat approximately 90% of the cases in their respective regions. The remaining centers have reported all the patients who were treated during certain time periods, but not for the entire 25-year period. Results - 59% of patients were referred to a sarcoma center untouched, i.e. before any attempt at open biopsy. There was an improvement from 52% during the first 5 years to 70% during the last 5 years. 50% had wide or better margins at surgery. Wide margins are now achieved less often than 20 years ago, in parallel with an increase in the use of radiotherapy. For the centers that consistently report, 97% of surviving patients are followed for more than 4 years. Metastasis-free survival (MFS) increased from 67% to 73% during the 25-year period. Interpretation - The Register is considered to be representative of extremity and trunk wall sarcoma disease in the population of Scandinavia, treated at the reporting centers. There were no clinically significant differences in treatment results at these centers.


Asunto(s)
Sarcoma/terapia , Neoplasias de los Tejidos Blandos/terapia , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biopsia , Niño , Preescolar , Extremidades , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Clasificación del Tumor , Recurrencia Local de Neoplasia/epidemiología , Derivación y Consulta/estadística & datos numéricos , Sistema de Registros , Sarcoma/diagnóstico , Sarcoma/epidemiología , Sarcoma/patología , Sarcoma/secundario , Países Escandinavos y Nórdicos/epidemiología , Neoplasias de los Tejidos Blandos/diagnóstico , Neoplasias de los Tejidos Blandos/epidemiología , Neoplasias de los Tejidos Blandos/patología , Torso
3.
J Surg Oncol ; 112(8): 853-60, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26482729

RESUMEN

AIMS: The objectives of this study were to present changes in referral patterns, treatment and survival in patients with high-grade malignant bone sarcoma in Sweden and Norway based on data in the Scandinavian Sarcoma Group (SSG) Central Register. METHOD: Data on 1,437 patients with diagnosis 1986-2010 was analyzed. RESULTS: Osteosarcoma was the most frequentl diagnosis (45%), followed by Ewing sarcoma (21%) and chondrosarcoma (17%). Thirty-one percent of Swedish and 41% of Norwegian patients had tumors in the axial skeleton. Eighty-six percent of extremity tumors and 66% of axial tumors were referred to a sarcoma center prior to unplanned surgery or biopsy. During the past decade, limb salvage surgery has risen from under 50% to over 80%. Five-year overall survival in non-metastatic osteosarcoma was 70% for extremity tumors, and 35% for axial tumors. No improvement in osteosarcoma survival was observed during the last decade. Five-year survival in Ewing sarcoma improved from 50% to 69%. CONCLUSION: Referral patterns in bone sarcomas have improved. However, greater efforts should be dedicated to improving referral of patients with possible tumors in the axial skeleton to multidisciplinary teams (MDTs). Overall survival of patients with high-grade malignant bone sarcomas in Sweden and Norway is in line with other reports.


Asunto(s)
Neoplasias Óseas/diagnóstico , Neoplasias Óseas/terapia , Derivación y Consulta/estadística & datos numéricos , Sistema de Registros , Sarcoma/diagnóstico , Sarcoma/terapia , Adolescente , Adulto , Anciano , Neoplasias Óseas/mortalidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Noruega/epidemiología , Sarcoma/mortalidad , Suecia/epidemiología , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
4.
BMC Cancer ; 12: 493, 2012 Oct 25.
Artículo en Inglés | MEDLINE | ID: mdl-23098538

RESUMEN

BACKGROUND: We recently developed two Bayesian networks, referred to as the Bayesian-Estimated Tools for Survival (BETS) models, capable of estimating the likelihood of survival at 3 and 12 months following surgery for patients with operable skeletal metastases (BETS-3 and BETS-12, respectively). In this study, we attempted to externally validate the BETS-3 and BETS-12 models using an independent, international dataset. METHODS: Data were collected from the Scandinavian Skeletal Metastasis Registry for patients with extremity skeletal metastases surgically treated at eight major Scandinavian referral centers between 1999 and 2009. These data were applied to the BETS-3 and BETS-12 models, which generated a probability of survival at 3 and 12 months for each patient. Model robustness was assessed using the area under the receiver-operating characteristic curve (AUC). An analysis of incorrect estimations was also performed. RESULTS: Our dataset contained 815 records with adequate follow-up information to establish survival at 12 months. All records were missing data including the surgeon's estimate of survival, which was previously shown to be a first-degree associate of survival in both models. The AUCs for the BETS-3 and BETS-12 models were 0.79 and 0.76, respectively. Incorrect estimations by both models were more commonly optimistic than pessimistic. CONCLUSIONS: The BETS-3 and BETS-12 models were successfully validated using an independent dataset containing missing data. These models are the first validated tools for accurately estimating postoperative survival in patients with operable skeletal metastases of the extremities and can provide the surgeon with valuable information to support clinical decisions in this patient population.


Asunto(s)
Neoplasias Óseas/mortalidad , Neoplasias Óseas/secundario , Modelos Estadísticos , Adulto , Anciano , Anciano de 80 o más Años , Teorema de Bayes , Neoplasias Óseas/cirugía , Femenino , Humanos , Funciones de Verosimilitud , Masculino , Persona de Mediana Edad , Países Escandinavos y Nórdicos/epidemiología , Análisis de Supervivencia , Adulto Joven
5.
Acta Oncol ; 50(3): 435-40, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20545566

RESUMEN

BACKGROUND: Bone sarcomas in Sweden are generally referred to a multidisciplinary team at specialized sarcoma centers. This practice is strictly followed for sarcomas of long bones, but not for chest wall chondrosarcomas. Delay in diagnosis and treatment is often considerable for bone sarcomas. This report focuses on the symptoms and diagnostic problems of chest wall chondrosarcoma and factors related to long doctor's delay. METHODS: The material included all 106 consecutive patients with chondrosarcoma of the chest wall diagnosed in Sweden 1980-2002. Pathological specimens were re-evaluated and graded by the Scandinavian Sarcoma Group pathology board. Files from the very first medical visit for symptoms related to the chondrosarcoma were traced and used to characterize the initial symptoms and calculate patient's and doctor's delay. RESULTS: The most prominent initial symptom for the chest wall chondrosarcomas was a palpable mass found in 69% (73/106) of the patients at the first visit. Two-thirds of the patients experienced no local chest pain. A tumor was suspected at the first visit in 83% of the patients. Patients delay was median 3 (0-118) months and doctor's delay was 4.5 (0.1-197) months. Doctor's delay was >6 months for 40% of the patients. Patients with an initial plain chest radiograph interpreted as normal (35 patients), and/or normal or inconclusive results of a fine-needle aspiration biopsy had longer doctor's delay. Fine-needle aspiration cytology done at non-specialty units resulted in only 26% correct malignant diagnoses; at sarcoma centers 94% were correctly diagnosed. Long total delay was unfavorable. Patients who died from the chondrosarcoma had longer total delay (p<0.05). CONCLUSION: Chest wall chondrosarcoma presents as a lump, usually painless. Plain chest radiographs and fine-needle aspiration cytology, when done at a non-specialty center, are often normal or inconclusive. Patients should be referred to sarcoma centers for diagnosis and treatment.


Asunto(s)
Neoplasias Óseas/diagnóstico , Condrosarcoma/diagnóstico , Diagnóstico Tardío/estadística & datos numéricos , Neoplasias Torácicas/diagnóstico , Pared Torácica/patología , Neoplasias Óseas/epidemiología , Neoplasias Óseas/patología , Condrosarcoma/epidemiología , Condrosarcoma/patología , Estudios de Cohortes , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Persona de Mediana Edad , Población , Opinión Pública , Sistema de Registros , Estudios Retrospectivos , Países Escandinavos y Nórdicos/epidemiología , Suecia/epidemiología , Neoplasias Torácicas/epidemiología , Neoplasias Torácicas/patología
6.
Clin Cancer Res ; 15(8): 2685-94, 2009 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-19336518

RESUMEN

PURPOSE: Histologic grade is currently the best predictor of clinical course in chondrosarcoma patients. Grading suffers, however, from extensive interobserver variability and new objective markers are needed. Hence, we have investigated DNA copy numbers in chondrosarcomas with the purpose of identifying markers useful for prognosis and subclassification. EXPERIMENTAL DESIGN: The overall pattern of genomic imbalances was assessed in a series of 67 chondrosarcomas using array comparative genomic hybridization. Statistical analyses were applied to evaluate the significance of alterations detected in subgroups based on clinical data, morphology, grade, tumor size, and karyotypic features. Also, the global gene expression profiles were obtained in a subset of the tumors. RESULTS: Genomic imbalances, in most tumors affecting large regions of the genome, were found in 90% of the cases. Several apparently distinctive aberrations affecting conventional central and peripheral tumors, respectively, were identified. Although rare, recurrent amplifications were found at 8q24.21-q24.22 and 11q22.1-q22.3, and homozygous deletions of loci previously implicated in chondrosarcoma development affected the CDKN2A, EXT1, and EXT2 genes. The chromosomal imbalances in two distinct groups of predominantly near-haploid and near-triploid tumors, respectively, support the notion that polyploidization of an initially hyperhaploid/hypodiploid cell population is a common mechanism of chondrosarcoma progression. Increasing patient age as well as tumor grade were associated with adverse outcome, but no copy number imbalance affected metastasis development or tumor-associated death. CONCLUSION: Despite similarities in the overall genomic patterns, the present findings suggest that some regions are specifically altered in conventional central and peripheral tumors, respectively.


Asunto(s)
Neoplasias Óseas/genética , Neoplasias Óseas/patología , Condrosarcoma/genética , Condrosarcoma/patología , Cromosomas Humanos Par 11/genética , Cromosomas Humanos Par 8/genética , Inhibidor p16 de la Quinasa Dependiente de Ciclina/genética , Inhibidor p16 de la Quinasa Dependiente de Ciclina/metabolismo , Femenino , Dosificación de Gen/genética , Perfilación de la Expresión Génica , Humanos , Masculino , Metaloproteasas/genética , Metaloproteasas/metabolismo , Persona de Mediana Edad , N-Acetilglucosaminiltransferasas/genética , N-Acetilglucosaminiltransferasas/metabolismo , Eliminación de Secuencia/genética
7.
Int J Spine Surg ; 13(2): 186-191, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31131219

RESUMEN

BACKGROUND: We investigated the outcome of surgical treatment of patients with radiosensitive hematological malignancies presenting with spinal cord compression. METHODS: Retrospective review of 50 patients who had treatment between 1993 and 2012. RESULTS: The neurological outcome was favorable in 35 patients, stable in 12, whereas 3 patients deteriorated. Decompression within 48 hours from referral was associated with a superior neurological recovery (P = .001). Complications were noted in 11 patients, and 6 of these underwent secondary surgery. Early (30-day) mortality was 8%. Radiotherapy was associated with increased incidence of complications (χ2 = 0.009). Patients who had low blood hemoglobin preoperatively as well as those who remained totally bedridden postoperatively had an inferior overall survival rate (P < .001). CONCLUSION: Patients with cord compression from hematological malignancy benefit from early surgical decompression. There is an inherent high risk for complications, which increases further if radiotherapy is given. Patients failing to ambulate after surgery have a poor prognosis.

8.
Int J Radiat Oncol Biol Phys ; 71(4): 1196-203, 2008 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-18207661

RESUMEN

PURPOSE: Adjuvant radiotherapy has during the past decades become increasingly used in the treatment of localized soft tissue sarcoma. We evaluated the effect of radiotherapy (RT) on local recurrence rates (LRRs) in Scandinavia between 1986 and 2005. METHODS AND MATERIALS: A total of 1,093 adult patients with extremity or trunk wall soft tissue sarcoma treated at four Scandinavian sarcoma centers were stratified according to the treatment period (1986-1991, 1992-1997, and 1998-2005). The use of adjuvant RT, quality of the surgical margin, interval between surgery and RT, and LRR were analyzed. The median follow-up was 5 years. RESULTS: The use of RT (77% treated postoperatively) increased from 28% to 53%, and the 5-year LRR decreased from 27% to 15%. The rate of wide surgical margins did not increase. The risk factors for local recurrence were histologic high-grade malignancy (hazard ratio [HR], 5), an intralesional (HR, 6) or marginal (HR, 3) surgical margin, and no RT (HR, 3). The effect of RT on the LRR was also significant after a wide margin resection and in low-grade malignant tumors. The LRR was the same after preoperative and postoperative RT. The median interval from surgery to the start of RT was 7 weeks, and 98% started RT within 4 months. The LRR was the same in patients who started treatment before and after 7 weeks. CONCLUSION: The results of our study have shown that adjuvant RT effectively prevents local recurrence in soft tissue sarcoma, irrespective of the tumor depth, malignancy grade, and surgical margin status. The effect was most pronounced in deep-seated, high-grade tumors, even when removed with a wide surgical margin.


Asunto(s)
Recurrencia Local de Neoplasia/epidemiología , Recurrencia Local de Neoplasia/prevención & control , Sarcoma/radioterapia , Sarcoma/cirugía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Extremidades , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Noruega/epidemiología , Radioterapia Adyuvante/estadística & datos numéricos , Estudios Retrospectivos , Sarcoma/epidemiología , Suecia/epidemiología , Tórax , Resultado del Tratamiento
9.
Acta Orthop ; 79(1): 86-93, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18283578

RESUMEN

BACKGROUND: Giant cell tumors of bone rarely metastasize but often recur locally after surgery. There is limited knowledge about the risk of recurrence related to different types of treatment. PATIENTS AND METHODS: We analyzed factors affecting the local recurrence rate in 294 patients with giant cell tumors of the extremities using prospectively collected material from 13 centers. The median follow-up time was 5 (0.2-18) years. RESULTS: A local recurrence was diagnosed in 57 of 294 patients (19%). The overall 5-year local recurrence rate was 0.22. Univariate analysis identified young age and intralesional surgery to be associated with a higher risk of recurrence. Based on multivariate analysis, the relative risk was 2.4-fold for intralesional surgery compared to more extensive operative methods. There was no correlation between tumor size, tumor extension, sex of the patient, tumor location, or fracture at diagnosis and outcome. In the subgroup of 200 patients treated with intralesional surgery, the method of filling (cement or bone) was known for 194 patients and was statistically highly significant in favor of the use of cement. INTERPRETATION: Intralesional surgery should be the first choice in most giant cell tumors, even in the presence of a pathological fracture. After thorough evacuation, the cavity should be filled with cement.


Asunto(s)
Neoplasias Óseas/cirugía , Cementación , Tumor Óseo de Células Gigantes/cirugía , Osteosarcoma/cirugía , Adolescente , Adulto , Anciano , Cementos para Huesos , Trasplante Óseo , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Pierna , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/etiología , Estudios Prospectivos , Factores de Tiempo , Resultado del Tratamiento
10.
Eur J Cancer ; 99: 78-85, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29929092

RESUMEN

PURPOSE: To investigate the outcome following adjuvant doxorubicin and ifosfamide in a prospective non-randomised study based on a soft tissue sarcoma (STS) patient subgroup defined by specific morphological characteristics previously shown to be at a high-risk of metastatic relapse. The expected 5-year cumulative incidence of metastases in patients with this risk profile has previously been reported to be about 50% without adjuvant chemotherapy. METHODS: High-risk STS was defined as high-grade morphology (according to the Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade II-III) and either vascular invasion or at least two of the following criteria: tumour size ≥8.0 cm, infiltrative growth and necrosis. Six cycles of doxorubicin (60 mg/m2) and ifosfamide (6 g/m2) were given. Postoperative accelerated radiotherapy was applied and scheduled between cycles 3 and 4. RESULTS: For the 150 eligible patients, median follow-up time for metastases-free survival was 3.9 years (range 0.2-8.7). Five-year metastases-free survival (MFS) was 70.4% (95% confidence interval [CI]: 63.1-78.4) with a local recurrence rate of 14.0% (95% CI: 7.8-20.2). For overall survival (OS), the median follow-up time was 4.4 years (range: 0.2-8.7). The five-year OS was 76.1% (95% CI: 68.8-84.2). Tumour size, deep location and reduced dose intensity (<80%) had a negative impact on survival. Toxicity was moderate with no treatment-related death. CONCLUSIONS: A benefit of adjuvant chemotherapy, compared to similar historical control groups, was demonstrated in STS patients with defined poor prognostic factors. Vascular invasion, tumour size, growth pattern and necrosis may identify patients in need of adjuvant chemotherapy.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Recurrencia Local de Neoplasia/epidemiología , Sarcoma/epidemiología , Neoplasias de los Tejidos Blandos/terapia , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Quimioterapia Adyuvante/métodos , Relación Dosis-Respuesta a Droga , Doxorrubicina/farmacología , Doxorrubicina/uso terapéutico , Femenino , Estudios de Seguimiento , Humanos , Ifosfamida/farmacología , Ifosfamida/uso terapéutico , Incidencia , Masculino , Persona de Mediana Edad , Invasividad Neoplásica/patología , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/prevención & control , Estudios Prospectivos , Radioterapia Adyuvante/métodos , Factores de Riesgo , Sarcoma/irrigación sanguínea , Sarcoma/prevención & control , Sarcoma/secundario , Neoplasias de los Tejidos Blandos/irrigación sanguínea , Neoplasias de los Tejidos Blandos/mortalidad , Neoplasias de los Tejidos Blandos/patología , Análisis de Supervivencia , Resultado del Tratamiento , Adulto Joven
11.
Orthopedics ; 38(5): e401-6, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25970367

RESUMEN

Limb-preserving surgery using modular megaprostheses for the reconstruction of large skeletal defects is currently the preferred treatment for sarcomas. The authors report the postoperative outcomes after skeletal resection for lower extremity sarcomas and the use of the METS cemented modular implant system (Stanmore Implants, Hertfordshire, United Kingdom) for reconstruction. They retrospectively studied 52 consecutive patients operated on from 2003 to 2012. There were 27 distal femur prostheses, 13 proximal femur, 11 proximal tibia, and 1 total femur implants. Patients were followed for a mean of 4.3 years. Overall patient survival, prosthesis survival, limb salvage rate, and secondary complications were documented. Five years postoperatively, prosthesis survival was 79%. Complications warranting implant revision surgery were documented in 15% of patients, whereas complications warranting surgery of any kind were observed in 27% of the patients. Nonmechanical complications, namely local relapse of the tumor and prosthetic infection, were the most common cause of prosthetic failure, accounting for 88% of major revision surgeries and 100% of amputations. Mechanical complications were rare, observed in only 6% of patients. No patients required secondary revision surgery. The limb salvage rate was 89%. Overall patient survival was 79% at 5 years and 71% at 10 years. The low risk for mechanical complications and the high limb salvage rate support the use of the METS modular megaprostheses for the reconstruction of skeletal defects following lower limb sarcoma surgery.


Asunto(s)
Miembros Artificiales/clasificación , Neoplasias Óseas/cirugía , Recuperación del Miembro/métodos , Extremidad Inferior/cirugía , Procedimientos Ortopédicos/métodos , Procedimientos de Cirugía Plástica/métodos , Sarcoma/cirugía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Amputación Quirúrgica , Neoplasias Óseas/mortalidad , Niño , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Diseño de Prótesis , Falla de Prótesis , Estudios Retrospectivos , Sarcoma/mortalidad , Tasa de Supervivencia , Resultado del Tratamiento , Reino Unido , Adulto Joven
12.
J Bone Joint Surg Am ; 97(21): 1756-66, 2015 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-26537163

RESUMEN

BACKGROUND: The Swedish Cancer Registry (founded in 1958) constitutes a unique resource for epidemiological studies of giant cell tumor of bone with potential for use for population-based studies of incidence over time. The aim of this study was to provide what we believe is the first modern population-based assessment of the incidence trends of giant cell tumor, a unique osteoclastogenic lytic stromal tumor with both benign and malignant histological forms, and to compare the findings with data from the same registry on osteosarcoma, a tumor that may display similar histological characteristics. METHODS: Cases were identified with use of codes for pathological bone tumor (International Classification of Diseases [ICD]-7 196). Specific morphological coding distinguishes benign (PAD 741) from malignant giant cell tumor (PAD 746) and osteosarcoma (PAD 766). RESULTS: During the period of 1958 to 2011, 4625 bone tumors were reported, including 505 giant cell tumors (383 benign and 122 malignant) and 1152 osteosarcomas. From 1958 to 1982 the ratio of malignant to benign giant cell tumors was 1.3, whereas from 1983 to 2011 the ratio inverted to 0.09, suggesting a change in the reporting or diagnosis of malignant or benign cases. Cases of giant cell tumor diagnosed from 1983 to 2011 displayed an age and sex distribution (median age at diagnosis, 34.0 years; 54% female) that were consistent with those in large published case series but differed from those in 1958 to 1982 (median age at diagnosis, 31.5 years; 48% female). The most current data (1983 to 2011) showed the giant cell tumor incidence in Sweden to be 1.3 per million per year, while the osteosarcoma incidence was 2.3 per million per year. CONCLUSIONS: Early Swedish Cancer Registry data (1958 to 1982) revealed a higher proportion of malignant giant cell tumors than seen in large sequential case series and a distinct age and sex profile compared with more recent data (1983 to 2011). This likely represents changes in the diagnostic workup and introduction of multidisciplinary review of giant-cell-containing tumors around 1982. Recent data may reflect the impact of expert centralized biopsy and multidisciplinary case review and more comprehensive reporting of benign giant cell tumors.


Asunto(s)
Neoplasias Óseas/epidemiología , Tumor Óseo de Células Gigantes/epidemiología , Osteosarcoma/epidemiología , Adolescente , Adulto , Distribución por Edad , Neoplasias Óseas/patología , Niño , Preescolar , Femenino , Tumor Óseo de Células Gigantes/patología , Humanos , Incidencia , Lactante , Recién Nacido , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Osteosarcoma/patología , Sistema de Registros , Estudios Retrospectivos , Distribución por Sexo , Suecia/epidemiología , Factores de Tiempo , Adulto Joven
13.
Ortop Traumatol Rehabil ; 5(2): 164-6, 2003 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-18033999

RESUMEN

Important improvement of function can be gained by surgical treatment. However, the complication rate is high and many patients die of their disease within the first months of surgery. The indication for surgical treatment in spinal metastases at our institution has been neurological deficit due to epidural compression. In my view, other modalities such as radiotherapy and advanced pain management will relieve pain in the vast majority of patients, and I have not considered pain as a sole indication for surgery. Furthermore, all surgery for metastatic disease is palliative and will not significantly influence survival. Therefore, attempts at marginal or wide excision in solitary metastases of e. g. breast cancer as meaningless. Intralesional excision and reconstruction with cement, is however, often indicated to relieve spinal cord compression and restore spinal stability.

14.
Cancer Genet ; 206(7-8): 299-303, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23938179

RESUMEN

Soft tissue tumors in children under one year of age (infants) are rare. The etiology is usually unknown, with external factors or congenital birth defects and hereditary syndromes being recognized in only a small proportion of the cases. We ascertained the cytogenetic findings in 16 infants from whom tumor tissue had been obtained during a 25-year period. In eight of them, single nucleotide polymorphism (SNP) array analyses could also be performed. No constitutional chromosome aberrations were detected, and assessment of clinical files did not reveal any congenital or later anatomical defects. Three tumors--one infantile fibrosarcoma, one embryonal rhabdomyosarcoma, and one angiomatoid fibrous histiocytoma (AFH)--had abnormal karyotypes. As the AFH had an exchange between chromosome arms 12p and 15q, additional fluorescence in situ hybridization and reverse transcription-polymerase chain reaction analyses were performed, unexpectedly revealing an ETV6/NTRK3 fusion. Three of the eight tumors, including the AFH with an abnormal karyotype, analyzed by SNP array showed aberrations (loss of heterozygosity or imbalances). The present series suggests that the addition of array-based technologies is valuable for detecting underlying pathogenetic mechanisms.


Asunto(s)
Neoplasias de los Tejidos Blandos/genética , Edad de Inicio , Análisis Citogenético , Femenino , Fibrosarcoma/epidemiología , Fibrosarcoma/genética , Fibrosarcoma/patología , Humanos , Lactante , Recién Nacido , Masculino , Análisis por Micromatrices/métodos , Proteínas de Fusión Oncogénica/genética , Polimorfismo de Nucleótido Simple , Proteínas Proto-Oncogénicas c-ets/genética , Receptor trkC/genética , Proteínas Represoras/genética , Estudios Retrospectivos , Rabdomiosarcoma Embrionario/epidemiología , Rabdomiosarcoma Embrionario/genética , Rabdomiosarcoma Embrionario/patología , Neoplasias de los Tejidos Blandos/diagnóstico , Neoplasias de los Tejidos Blandos/epidemiología , Proteína ETS de Variante de Translocación 6
15.
J Thorac Cardiovasc Surg ; 137(3): 610-4, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19258076

RESUMEN

OBJECTIVES: Chondrosarcoma of the chest wall is the most frequent primary malignant chest wall tumor. Surgery remains the only effective treatment. Sarcoma treatment in Sweden is centralized to sarcoma centers; however, sarcomas of the chest wall have also been handled by thoracic and general surgeons. METHODS: One hundred six consecutive reports of chondrosarcomas of the rib and sternum over a 22-year period (1980 to 2002) were studied, with a median of 9 (4 to 23) years of follow-up for survivors. Clinical files were gathered and pathologic specimens reviewed and graded 1 to 4 by the Scandinavian sarcoma pathology group. Surgical margins were defined as wide, marginal, or intralesional. RESULTS: Ninety-seven patients were treated with a curative intent. Patients operated with wide surgical margins had a 10-year survival of 92% compared with 47% for those with intralesional resections. The 10-year survival was 75% for patients treated at sarcoma centers and 59% for those treated by thoracic or general surgeons. Local recurrence rate was highly dependent of the surgical margins-4% after wide resections and 73% after intralesional resections. The proportion of intralesional resections was higher outside sarcoma centers. Prognostic factors (multivariate analysis) for local recurrence included surgical margin and histological grade; for metastases, prognostic factors included histologic grade, tumor size, and local recurrence. Metastases occurred in 21 of the patients and only 2 were cured. CONCLUSIONS: Patients operated with wide surgical margins resulted in fewer local recurrences and better overall survival. Patients with chest wall tumors should be referred to sarcoma centers and not to general thoracic surgery clinics for diagnosis and treatment.


Asunto(s)
Neoplasias Óseas/cirugía , Condrosarcoma/cirugía , Costillas , Esternón , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Países Escandinavos y Nórdicos , Resultado del Tratamiento , Adulto Joven
16.
Cancer ; 113(7): 1649-56, 2008 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-18720363

RESUMEN

BACKGROUND: The aim was to study the clinicopathological characteristics, treatment, and outcome of liposarcoma in an unselected, population-based patient sample, and to establish whether treatment was according to the Scandinavian Sarcoma Group (SSG) treatment guidelines. METHODS: The SSG Pathology Board reviewed 319 liposarcoma cases reported between 1986 and 1998. After the review, 237 patients without metastasis were analyzed for local recurrence rate in relation to surgical margins, radiotherapy, occurrence of metastasis, and survival. RESULTS: Seventy-eight percent of the patients were primarily operated on at a sarcoma center, 45% with wide margins. All patients operated on outside the center had nonwide margins. Low-grade lesions constituted 67% of cases. Despite nonwide surgery, only 58% of high-grade lesions were treated with postoperative radiotherapy. The risk of local recurrence after nonwide surgery, without irradiation, was 47% for high-grade lesions. The estimated 10-year, local recurrence-free and metastasis-free survival in the low-grade group was 87% and 95%, respectively. In the high-grade group, it was 75% and 61%, respectively. Independent adverse prognostic factors for local recurrence were surgery outside a sarcoma center and histological type dedifferentiated liposarcoma. For metastases, they were old age, large tumor size, high grade, and histological type myxoid liposarcoma with a round cell component. Radiotherapy showed significant effect on local recurrence rate for the same grade and margin. CONCLUSIONS: Patients with liposarcoma should be treated at specialized centers. Postoperative radiotherapy decreases the local recurrence rate. To maintain quality and provide support for further trials, reporting to quality registers is crucial.


Asunto(s)
Liposarcoma/radioterapia , Liposarcoma/cirugía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Recurrencia Local de Neoplasia , Pronóstico , Radioterapia Adyuvante , Sistema de Registros , Países Escandinavos y Nórdicos , Análisis de Supervivencia , Resultado del Tratamiento
17.
Acta Orthop ; 78(6): 840-4, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18236193

RESUMEN

BACKGROUND AND PURPOSE: Doctor's delay in diagnosing Ewing sarcoma is often long. We examined the initial symptoms of Ewing sarcoma of the rib to find characteristics that could help to shorten the delay in diagnosis and hopefully influence the prognosis. PATIENTS AND METHODS: We examined the records from the first visit for symptoms related to Ewing sarcoma of the rib in 26 consecutive patients, all of whom were <30 years of age and had been diagnosed between 1981 and 2000. All patients had a minimum of 5 years follow-up. RESULTS: A tumor was suspected at the first visit in only 5 of the 26 patients; pleurisy was the most common misdiagnosis. 23 patients complained of pain, localized or pleuritic, and 11 had a palpable mass. 15 of the 26 patients had chest radiographs taken at the first visit, but a tumor was suspected in only 4 cases. The most common radiographic finding was pleural effusion--diagnosed in 10 of the 15 patients. 23 patients were operated. It is noteworthy that in 6 patients no tumor was suspected before surgery. 12 patients died from the Ewing sarcoma. Median survival was 2.4 years. Doctor's delay was median 3.0 (0-10) months, but it exceeded 7 months in 4 patients. Patient's delay was 2.5 (0-10) months. INTERPRETATION: The most important clinical finding in Ewing sarcoma of the rib was a palpable mass and pleural effusion. Both findings are rare in this age group and should be thoroughly investigated.


Asunto(s)
Neoplasias Óseas/diagnóstico , Costillas , Sarcoma de Ewing/diagnóstico , Adolescente , Adulto , Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/mortalidad , Neoplasias Óseas/cirugía , Niño , Errores Diagnósticos , Femenino , Estudios de Seguimiento , Humanos , Masculino , Derrame Pleural/diagnóstico , Pleuresia/diagnóstico , Pronóstico , Radiografía , Costillas/diagnóstico por imagen , Sarcoma de Ewing/diagnóstico por imagen , Sarcoma de Ewing/mortalidad , Sarcoma de Ewing/cirugía , Tasa de Supervivencia , Factores de Tiempo
18.
Genes Chromosomes Cancer ; 46(6): 594-606, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17370328

RESUMEN

Conventional lipomas harbor karyotypic changes that could be subdivided into four, usually mutually exclusive, categories: rearrangement, in particular through translocations, of chromosome bands 12q13-15, resulting in deregulation of the HMGA2 gene, loss of material from or rearrangement of chromosome 13, supernumerary ring or giant marker chromosomes, and aberrations of chromosome band 6p21. In the present study, 272 conventional lipomas, two-thirds of them deep-seated, with acquired clonal chromosome changes were assessed with regard to karyotypic and clinical features. A nonrandom distribution of breakpoints and imbalances could be confirmed, with 83% of the cases harboring one or more of the previously known cytogenetic hallmarks. Correlation with clinical features revealed that lipomas with rings/giant markers were larger, occurred in older patients, were more often deep-seated, and seemed to have an increased tendency to recur locally, compared with tumors with other chromosome aberrations. The possible involvement of the HMGA2 gene in cases that did not show any of the characteristic cytogenetic changes was further evaluated by locus-specific metaphase fluorescence in situ hybridization (FISH) and RT-PCR, revealing infrequent cryptic disruption of the gene but abundant expression of full length or truncated transcripts. By FISH, we could also show that breakpoints in bands 10q22-23 do not affect the MYST4 gene, whereas breakpoints in 6p21 or 8q11-12 occasionally target the HMGA1 or PLAG1 genes, respectively, also in conventional lipomas.


Asunto(s)
Aberraciones Cromosómicas , Cromosomas Humanos Par 13/genética , Proteína HMGA2/genética , Cariotipificación/métodos , Lipoma/genética , Neoplasias/genética , Neoplasias de los Tejidos Blandos/genética , Adolescente , Adulto , Niño , Preescolar , Estudios de Cohortes , Femenino , Proteína HMGA2/metabolismo , Humanos , Hibridación Fluorescente in Situ , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
19.
Eur Spine J ; 15(2): 196-202, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15744540

RESUMEN

We present survival, neurological function, and complications in a consecutive series of 282 patients operated for spinal metastases from January 1990 to December 2001. Our main surgical indication throughout this time period was neurological deficit rather than pain. Metastases from cancer of the prostate accounted for 40%, breast 15%, kidney 8%, and lung 7%. In 78% the level of decompression was thoracic and lumbar in 22%. Thirteen percent had a single metastases only, 64% had multiple skeletal metastases, and 23% had non-skeletal metastases also. Preoperatively 64% were non-walkers (Frankel A-C), 30% could walk with aids (Frankel D) and 8% had normal motor function (Frankel E). Posterior decompression and stabilization was applied in 212 patients, 47 had laminectomy only, and 23 had anterior decompressions and reconstruction. Complications were recorded at a level of 20%, and systemic complications were often associated with early death. The survival rate was 0.63 at 3 months, 0.47 at 6 months, 0.30 at 1 year, and 0.16 at 2 years. Twelve of 255 (5%) patients with motor deficits were worsened postoperatively, whereas 179 (70%) improved at least one Frankel grade. The ability to walk postoperatively was retained during follow-up in more than 80% of the patients. This study shows that important improvement of function can be gained by surgical treatment, but the complication rate was high and many patients died of their disease within the first months of surgery.


Asunto(s)
Vértebras Lumbares/cirugía , Paraparesia/cirugía , Paraplejía/cirugía , Neoplasias de la Columna Vertebral/secundario , Vértebras Torácicas/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Descompresión Quirúrgica/efectos adversos , Descompresión Quirúrgica/mortalidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Paraparesia/mortalidad , Paraplejía/mortalidad , Estudios Prospectivos , Reoperación , Compresión de la Médula Espinal/cirugía , Neoplasias de la Columna Vertebral/mortalidad , Neoplasias de la Columna Vertebral/cirugía , Resultado del Tratamiento
20.
J Clin Oncol ; 24(2): 315-20, 2006 Jan 10.
Artículo en Inglés | MEDLINE | ID: mdl-16330667

RESUMEN

PURPOSE: To investigate whether previously observed correlations between tumor karyotype and risk of metastases could be reproduced in an independent set of high-grade soft tissue sarcomas (STSs). PATIENTS AND METHODS: In a previous study on high-grade STSs with clonal chromosome aberrations, we identified a number of cytogenetic variables, besides tumor grade and size, that were associated with significantly increased risk of metastases. In the present study, we have tested the predictive value of these cytogenetic variables in a new set of 156 high-grade STSs, all located in the extremities or trunk wall. RESULTS: Of the 10 cytogenetic variables that turned out to provide prognostic information in the previous series, encompassing 122 trunk wall or extremity STSs, three were significantly associated with metastases also in the new series. In a final Cox regression analysis including these three cytogenetic variables, as well as tumor grade and size, on the combined series of 278 high-grade STSs, four parameters were found to be significantly associated with metastasis risk: tumor grade 3, tumor size > or = 5 cm, breakpoint in region 1p1, and gain of region 6p1. CONCLUSION: Our findings suggest that independent prognostic information may be gained from cytogenetic analysis of high-grade STS.


Asunto(s)
Aberraciones Cromosómicas , Sarcoma/genética , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Análisis de Regresión , Sarcoma/mortalidad , Sarcoma/patología , Sarcoma/secundario
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA